On March 16, HenGrui Medicine (600276.Sh), the company’s “drug registration certificate” was approved and the state of the drug registration and drug governance was provided and revised in the revised class and for the treatment of medium and severe pain after surgery. This medication is a small molecule agonist biased by an μ opioid receptor. So far, the annual research and event of related projects is investing, about 197.91 million yuan. (Caialshe)
Source link
